Based on analyses of conditioned medium from cocultures of MSCs, monocytes and NB cells, TGF-β1 was proposed to be a major contributor to MSC-/monocyte-induced protection from aNKC/dinutuximab treatment [182]. The gene discussed is TGFB1; the disease is neuroblastoma.